Event Overview
What is ibogaine? FDA to fast-track review of drugs for mental health
target="_blank">FDA moves to fast-track review of psilocybin and methylone for mental health CNN This cluster currently includes 2 articles from 2 sources.
This cluster currently includes 2 articles from 2 sources. Sources in this event include CNN, New York Post.
Left / left-center
1
Center
0
Right / right-center
1
FDA moves to fast-track review of psilocybin and methylone for mental health
Some psychedelic drugs, once considered fringe, are getting a step closer to possibly being approved for use as mental health treatments in the United States. The US Food and Drug Administration on Friday issued national priority vouchers to three companies studying these psychedelic-based medicines: psilocybin, the.
What is ibogaine? FDA to fast-track review of drugs for mental health
A mind-bending hallucinogen is moving out of the counterculture and into the clinic. The Food and Drug Administration on Friday greenlit the first-ever human clinical trial of an ibogaine derivative in the US, opening the door to testing the psychedelic drug as a potential treatment for alcohol-use disorder. The move.